Sygnature Discovery collaborates with DaltonTx to advance AI-enabled drug discovery capabilities

We have announced a strategic collaboration with DaltonTx, an AI technology company, to further strengthen our AI-enabled drug discovery capabilities. This collaboration is designed to accelerate medicinal chemistry decision-making while ensuring the highest standards of data security for our customers.

DaltonTx brings together expertise in drug discovery, software engineering, and artificial intelligence through its Dalton platform, which integrates data, models and experimental results into a unified environment to support biologics and small molecule discovery programs.

Through this collaboration, we are integrating DaltonTx into our existing computational and medicinal chemistry toolkit alongside proprietary and third-party technologies, including SygDesign, BullFrog AI, and Iktos. By combining these complementary AI platforms, we aim to enable faster, more informed decision-making across our discovery programs.

As part of this collaboration, we are conducting a retrospective evaluation using a legacy oncology program focused on a small molecule clinical candidate currently in Phase I development. This analysis is assessing whether the Dalton platform could have enabled us to reach candidate selection more efficiently through improved decision-making and a reduced synthesis burden.

“AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists,” said Simon Hirst, CEO of Sygnature Discovery. “By helping scientists make better-informed decisions earlier in the discovery process, we can reduce the number of compounds synthesized and tested, shorten DMTA cycles, and accelerate progression toward candidate selection.”

Unlike many standalone AI applications, Dalton combines a secure and scalable backend architecture with a natural language interface powered by agentic AI technologies, enabling scientists to drive ideation and problem-solving through conversational workflows.

“The next phase of AI in drug discovery is about impact,” said Garry Pairaudeau, CEO and Co-Founder of DaltonTx. “We believe the organisations that capture the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions. Dalton unifies data, models, and experimental results to capture what worked, what failed and why, with full context so judgement compounds over time. We are proud to collaborate with Sygnature Discovery to deliver tangible outcomes that translate into measurable value.”

This collaboration also addresses growing industry concerns around the use of proprietary data in AI-enabled environments. We ensure that customer data and AI models are compartmentalized on a per-program basis, so that customer information is never used to train models supporting other projects.

“Our approach ensures our customers can access the latest AI-enabled technologies without their data being used to train models for the benefit of others,” added Hirst. “We have well-established systems in place to securely manage customer data, and those same principles apply when deploying AI tools.”

We plan to extend validation of the Dalton platform into live customer programs as opportunities arise.

About Dalton^Tx

Dalton^Tx is building the intelligence backbone for modern drug discovery, fusing agentic AI, human expertise, and wet-lab experimentation into one continuously learning engine. By unifying data, models, and experimental results, all of which have historically been siloed and fragmented, Dalton’s platform learns in real time, looping experimental evidence back into a refinement cycle of unprecedented speed.

Dalton captures what worked, what failed and why, with full context and perfect memory, so judgement compounds over time. Agents propose strategies, evaluate trade-offs, and autonomously execute computational workflows; experiments are prioritised for maximum learning, with new data fed back immediately, while human experts set direction and interprets what the system uncovers.

The outcome is smarter decisions, fewer wasted experiments, and faster, more confident progress towards better molecules. Customers don’t just get better models; they get better judgement. A self-learning system will always outperform one that doesn’t. Speed and efficiency emerge naturally. The true breakthrough is smarter decision-making, and the confidence to tackle more complex biology, knowing that every cycle improves the next choice.

Founded on research from the University of Oxford and built by leaders with decades of experience behind AI discovery platforms at AstraZeneca and Exscientia, Dalton^Tx delivers reliable, secure, enterprise quality engineering – high performance scalable infrastructure that is readily deployed. Delivered as a secure, modular, plug and play cloud platform; Dalton integrates in days, not months.